Displaying items by tag: biotech

(New York)

Passive funds have seen a meteoric rise since the Financial Crisis, with AUM soaring by trillions. But within that huge growth, what have been the best returning passive funds? Financial Planning produced a slide show presenting the twenty best. The top performing funds list is dominated by the big three providers—BlackRock, Vanguard, and State Street, who also have 82% of all passive AUM. The top five returning funds are the SPDR S&P Biotech (XBI), Invesco Dynamic Pharmaceuticals ETF (PJP), the First Trust NYSE Arca Biotech ETF (FBT), the Invesco Nasdaq Internet ETF (PNQI), and the First Trust Dow Jones Internet ETF (FDN).

FINSUM: Looks like biotech and tech stocks had a great decade (nor surprise there). The rest of the top twenty is similarly dominated by tech and healthcare, but consumer stocks, defense, and semiconductors also show up.

(Washington)

There have been a handful of articles lately presenting how one can protect their portfolio from the current trade war (hint, stay away from food companies and autos). But there have been many fewer saying how to buy into the trade war. The answer is that investors should buy less vulnerable sectors, such as semiconductors and biotechnology, which will not be as impacted by tariffs. Banks are also likely to prosper as the economy continues its run.

FINSUM: We think the idea of biotech and banks is quite a solid one. Both seem to have little direct exposure to tariffs.

(New York)

A lot of investors are looking for income, and over the last several years it has been hard to come by. While yields are rising, they are still very low by historical standards. With that in mind, Barron’s has run a piece selecting the best income stocks from a sector not considered as much as it should be—biotech. Many biotech companies have strong overseas cash flow, and solid yields. For instance, Pfizer, which rose just over 13% last year, sports a 3.7% yield. Abbvie and Amgen are also good looking stocks, both offering dividends just below 3%. Eli Lilly, Johnson & Johnson, and Bristol-Myers Squibb are also names to look at.

FINSUM: These are definitely some good names to look at, especially as there has not been much focus on biotech for income over the last year.